GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CS Medica AS (STU:8G8) » Definitions » LT-Debt-to-Total-Asset

CS Medica AS (STU:8G8) LT-Debt-to-Total-Asset : 0.24 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CS Medica AS LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CS Medica AS's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.24.

CS Medica AS's long-term debt to total assets ratio declined from Sep. 2023 (0.33) to Sep. 2024 (0.24). It may suggest that CS Medica AS is progressively becoming less dependent on debt to grow their business.


CS Medica AS LT-Debt-to-Total-Asset Historical Data

The historical data trend for CS Medica AS's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CS Medica AS LT-Debt-to-Total-Asset Chart

CS Medica AS Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.57 0.05 0.02 0.33 0.24

CS Medica AS Quarterly Data
Sep19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.30 0.27 0.27 0.24

CS Medica AS LT-Debt-to-Total-Asset Calculation

CS Medica AS's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (A: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Sep. 2024 )/Total Assets (A: Sep. 2024 )
=1.158/4.879
=0.24

CS Medica AS's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=1.158/4.879
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CS Medica AS  (STU:8G8) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


CS Medica AS LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of CS Medica AS's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CS Medica AS Business Description

Comparable Companies
Traded in Other Exchanges
Address
Indiakaj 10, Copenhagen, DNK, 2100
CS Medica AS is engaged in developing, manufacturing, and commercializing over-the-counter medical device products containing cannabinoids currently focusing on cannabidiol for the treatment of psoriasis and arthritis. It operates in two business segments such as GalaxaPharma A/S responsible for distribution operation for marketing and sales direct-to-consumer, to retailers, and e-tail and CANNORDIC A/S is engaged in research and development, establishing of global business contracts, supply of CBD ingredients and production of finished products.

CS Medica AS Headlines

No Headlines